← All trials
NCT04222972
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2020
- Primary completion
- Sep 30, 2023
- Completion date
- Dec 31, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Blueprint Medicines CorporationLead sponsor
Drugs studied
Indications studied
- Adenocarcinoma
- Bronchial Diseases
- Carcinoma
- Carcinoma, Bronchogenic
- Carcinoma, Non-Small-Cell Lung
- Head and Neck Neoplasms
- Lung Diseases
- Lung Neoplasms
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Respiratory Tract Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Small Cell Lung Carcinoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.